Senzime’s Interim report January – September 2019

Press release: Uppsala, November 8, 2019. Senzime AB’s (publ) Interim report for January – September 2019 is now available on the company’s webbsite  www.senzime.com

New research data proves the value of accurate monitoring of patients after use of muscle relaxants

News: Uppsala, November 4, 2019. New evidence from the POPULAR study concludes that higher TOF-ratio before extubating reduces the risk of postoperative pulmonary complications.

Presented research from Mayo Clinic proves TetraGraph ease of use

News: Uppsala, October 24, 2019. The ASA (American Society of Anesthesiology) Annual Meeting is the premier venue for meeting physician anesthesiologists in the US with 14,000 attendees. During this year’s meeting, Assistant Professor J.Ross Renew MD at the Mayo Clinic in Jacksonville, Florida, held a poster presentation about the ease of application of various neuromuscular devices for routine monitoring.

Senzime receives FDA clearance

Press release: Uppsala, October 18, 2019. Senzime AB (publ) today announces that the company's medical technology system for monitoring neuromuscular blockade, TetraGraph, has received 510 (k) clearance by the US drug authority FDA. The clearance gives permission to market and sell TetraGraph in the US market.

100 TetraGraph systems to Japan after regulatory approval

Press release: Uppsala, August 30, 2019. In December 2016, Senzime AB (publ) signed a ten-year licensing agreement with Japanese Fukuda Denshi on the exclusive right to license and commercialize Senzime's TetraGraph system in the Japanese market. Fukuda are now about to initiate market launch as TetraGraph has obtained regulatory approval from the Japanese authorities. At the same time, Senzime receives a milestone payment of approximately SEK 1.8 million and 100 TetraGraph systems are shipped to Japan.

Senzime’s Interim report January – June 2019

Press release: Uppsala, August 22, 2019. Senzime AB’s (publ) Interim report for January – June 2019 is now available on the company’s webbsite www.senzime.com.

Communique From Extraodrinary General Meeting in Senzime AB (publ)

An extraordinary general meeting in Senzime AB (publ) was held on 21 August 2019 at the company’s offices on Ulls väg 29B in Uppsala whereby the shareholders primarily resolved on the following matters.

Notice of extraordinary general meeting in Senzime AB (publ)

The shareholders in Senzime AB (publ) reg. no. 556565-5734 (the “Company”) are hereby convened to an extraordinary general meeting on Wednesday 21 August 2019 at 15.00 at the Company’s office at Ulls väg 29B in Uppsala.

Senzime AB (publ) proposes a directed share issue of SEK 30 million to Länsförsäkringar, Handelsbanken, Segulah and the Crafoord family

Press release: Uppsala, July 25, 2019. The Board of Directors of Senzime AB (publ) ("Senzime" or the "Company") has decided to propose a directed share issue to a consortium consisting of a few strategically important investors, including Länsförsäkringar funds, Handelsbanken Microcap, Segulah and the Crafoord family to a value of SEK 30 million before issue costs and at a subscription price per share of SEK 8.90, corresponding to the average price in the last three trading days. Through the rights issue, the Company will receive SEK 30 million before issue costs to support the global launch of TetraGraph.

Senzime increases focus on the market for anesthesia monitoring and communicates sales targets

Press release: Uppsala, July 9, 2019. Senzime AB (publ) announces today that the company has chosen to increase its focus on the market for anesthesia monitoring as a result of the increased interest in the company's patient monitor, TetraGraph, which is in a global rollout phase. The company also communicates sales targets for 2019. 

TetraGraph receives regulatory approval and additional order from South Korea

Press release: Uppsala, July 8, 2019. Senzime AB (publ) today announces that TetraGraph has been approved in Korea and that the local distributor has followed up the order in May with an additional order comprising 30 TetraGraph systems.

Senzime contracts new CFO

Press release: Uppsala, June 18, 2019. Senzime AB (publ) today announces that the company has contracted Erik Bergman as new CFO and member of the management team. Erik succeeds Jessica Roxhed as CFO and takes office on October 1, 2019.

Senzime's board member Ulf Lindskog has passed away

Press release: Uppsala, June 7, 2019. It is with great sadness that we today announce that Ulf Lindskog passed away on June 5 after a period of illness at the age of 75. Ulf was elected member of Senzime's Board of Directors in 2010 and has been a highly appreciated member of Senzime's board. Our thoughts go to Ulf's family.

Senzime receives the first million order from South Korea

Press release: Uppsala, March 29, 2019. Senzime AB (publ) today announces that their distributor in Korea, Unimedics, has placed its first order for TetraGraph and its associated consumables at an order value of 1 million SEK due to be delivered during this week.

CFO transition in Senzime

Press release: Uppsala, May 14, 2019. Senzime AB (publ) today announces that Senzimes CFO Jessica Roxhed has resigned for personal reasons and will leave the company in August 2019.

Senzime exhibitor at SAMTIT

News: Uppsala, May 10, 2019. Senzime AB (publ) reports from SAMTIT Congress 8-10 May 2019

Communique from the annual general meeting in Senzime AB (publ)

The annual general meeting in Senzime AB (publ) was held on 8 May 2019 at the company’s offices on Ulls väg 29B in Uppsala whereby the shareholders primarily resolved on the following matters.

Senzime’s Interim report January – March 2019

Press release: Uppsala, May 8, 2019. Senzime AB’s (publ) Interim report for January – March 2018  is now available on the company’s webbsite www.senzime.com.

Senzime signs Nordic distribution agreement with Vingmed Holding A/S

Press release: Uppsala, May 6, 2019. Senzime AB (publ) today announces that it has signed an exclusive distribution agreement with Vingmed Holding A/S for the commercialization of TetraGraph in Sweden, Denmark, Norway and Finland.

Senzime Annual Summary 2018

News: Uppsala, April 25, 2019. Senzime AB’s (publ) annual summary for 2018 in English is now available on the company’s webbsite www.senzime.com.

Senzime’s Annual Report 2018

Uppsala, April 11, 2019. Senzime AB’s (publ) annual report for fiscal year 2018 (only in Swedish) is now available on the company’s webbsite www.senzime.com.

Notice of Annual General Meeting in Senzime ab (PUBL)

Press release: Uppsala, April 9, 2019. The shareholders in Senzime AB (publ) reg. no. 556565-5734 (the “Company”) are hereby convened to an annual general meeting on Wednesday 8 May 2019 at 15.00 at the Company’s office at Ulls väg 29B in Uppsala.

Senzime strengthens the management team within Sales and Marketing

Press release: Uppsala, March 28, 2019. Senzime AB (publ) today announced that the management team is strengthened with a VP Sales and a VP Marketing and Business development. This is in line with Senzime’s clear focus on international commercialization.

Senzime files new FDA application for TetraGraph

Press release: Uppsala, March 28, 2019. Senzime AB (publ) today announces the filing of the new 510(k) application to the US Food and Drug Administration (FDA) for the TetraGraph system. This filing is in line with previous communication and strategy to decrease the overall time to reach FDA clearance and subsequent introduction on the US market.

Market launch of the TetraGraph Viewer

Press release: Uppsala, March 26, 2019. Senzime AB (publ) today announces the launch of the TetraGraph Viewer, a new software, enabling data extraction and analytics from the TetraGraph patient monitor to a connected computer.

Norrlands Universitetssjukhus starts study with OnZurf Probe

Press release: Uppsala, March 25, 2019, Senzime (PUBL) today announces that Norrlands Universitetssjukhus has initiated a new exploratory pilot study with OnZurf probe. The study will include a total of 30 patients undergoing liver surgery.

Akademiska Sjukhuset in Uppsala new strategic customer to Senzime

Press release: Uppsala, March 20, 2019. Senzime AB (publ) today announces that the Department of Neuroanesthesia at the University Hospital in Uppsala has signed an agreement to buy TetraGraph systems. The agreement is of a minor value and initially includes five TetraGraph systems and associated disposable sensors.

Press conference regarding Senzime’s successful collaboration with the University of Debrecen

News: Uppsala, March 6, 2019. Senzime AB (publ) today announces that a press conference has been held at the University of Debrecen, Department of Anesthesiology and Intensive Care, focusing on their participation in testing and validating the TetraGraph during the last 5 years.

Senzime updates and optimizes strategy for FDA approval

Press release: Uppsala, February 15, 2019. Senzime AB (publ) today announces the intent to re-submit the existing 510(k) application to the US Food and Drug Administration (FDA). Based on an updated version of the TetraGraph, the existing 510(k) application will be re-submitted and Senzime thereby seeks to decrease the overall time to FDA approval.

Senzime’s Year-end Bulletin 2018

Press release: Uppsala, February 15, 2018. Senzime AB’s (publ) year-end bulletin is now available on the company’s webbsite www.senzime.com.

Pia Renaudin joins as new CEO at Senzime

Press release: Uppsala, February 7th, 2019. Pia Renaudin assumes her position as the new CEO of Senzime AB (publ).

Senzime receives milestone payment from Fukuda Denshi of approximately 2.4 million SEK

PRESS RELEASE: Uppsala, December 21, 2018. Senzime AB (publ) today announces the booking of a milestone payment of approximately 2.4 million SEK related to the license agreement and collaboration with Fukuda Denshi signed in 2016.

Senzime AB (publ) executes a directed share issue to two institutions – approximately SEK 28 million added before issue costs

Press Release: Uppsala, 12 December 2018.The Board of Directors of Senzime AB (publ) ("Senzime" or the “Company"), with the support of the authorization received at the AGM on May 8, 2018, has executed a directed share issue to Handelsbanken Fonder through the Svenska Microcapfond and Länsförsäkringar Fondförvaltning. The directed share issue comprises 4,000,000 shares at a subscription price of SEK 6.90 per share, equivalent to a premium of approximately two percent compared to the volume weighted average share price of the ten last trading days. Through the issue, the Company is granted approximately SEK 28 million before issue costs.

Pia Renaudin new CEO of Senzime

Press release: Uppsala, November 19, 2018: The Board of Senzime AB (publ) has today appointed Pia Renaudin as new Chief Executive Officer. Pia will start her new position in the first quarter of 2019, and will succeed the current CEO, Lena Söderström, who leaves Senzime after nearly six years. Catrin Molund, Director Marketing & Business Development at Senzime, will assume the role of acting CEO until Pia joins her position

Senzime’s Interim report January – September 2018

Press release: Uppsala, November 8, 2018. Senzime AB’s (publ) interim report for the period January - September is now available on the company’s webbsite www.senzime.com.

Senzime reports from the American Society of Anesthesiologists (ASA) Annual Meeting in San Francisco, USA

News: Uppsala, 17 October 2018.

Senzime signs additional distribution agreements in Europe

Press release: Uppsala, September 27, 2018. Senzime AB (publ) today announced that it signed exclusive distribution agreements for the commercialization of TetraGraph in Italy, Slovenia, Ukraine, Moldavia and Georgia.

Senzime at the Innovation Pavilion

News: Uppsala, September 4, 2018. Senzime AB (publ) has been selected to exhibit at the Innovation Pavilion at The MedTech Conference in Philadelphia, Pennsylvania September 24-26. Fourteen innovative companies have been given this opportunity by AdvaMed.   

Lena Söderström appointed Biotech Builder 2018

News: Uppsala, August 29, 2018. Lena Söderström has been appointed Biotech Builder 2018 of the year. The award is appointed to Life Science entrepreneurs who have made significant progress in the course of time, while being an inspiration for others in the industry.

Senzime’s Interim report quarter 2, 2018

Press release: Uppsala, August 22, 2018. Senzime AB’s (publ) interim report for the period January - June is now available on the company’s webbsite www.senzime.com.

TetraGraph Exhibition and Poster presentation at The Euroanaesthesia 2018 Annual Meeting, Copenhagen, Denmark, June 2-4

News: Uppsala, June 8, 2018. 

Resolutions at Senzime AB’s (publ) annual general meeting

Senzime AB (publ) (the “Company”) held its annual general meeting on May 8, 2018 in the Company’s premises on Ulls väg 29B in Uppsala.

Senzime’s Interim report January – March 2018

Uppsala, May 8, 2018. Senzime AB’s (publ) Interim report for January – March 2018 is now available on the company’s webbsite www.senzime.com.

TetraGraph Exhibition and Poster at The International Anesthesia Research Society’s (IARS) 2018 Annual Meeting, Chicago

News: Uppsala, May 4, 2018. 

Senzime ads 6 countries to the TetraGraph distribution network

Press Release: Uppsala, April 25, 2018. Senzime AB (publ) today announced that it signed exclusive distribution agreements for TetraGraph in Belgium, Netherlands, Luxemburg, Austria, Czech Republic and Slovakia.

Senzime’s Annual Report 2017

Press Release: Uppsala, April 17, 2018. Senzime AB’s (publ) annual report for fiscal year 2017 (only in Swedish) is now available on the company’s webbsite www.senzime.com.

Senzime signs distribution agreement in South Korea

Press release: Uppsala, March 19, 2018. Senzime AB (publ) today announced that it signed an exclusive distribution agreement with Unimedics (unimedics.co.kr) for the commercialization of the TetraGraph in South Korea. Compensation will be paid per unit in line with current industry compensation including a minimum guaranteed sale. The registration process is estimated to be finalized during 2019.

Senzime signs additional distribution agreements for the TetraGraph

Press Release: Uppsala, March 7, 2018. Senzime AB (publ) today announced that it signed exclusive distribution agreements for TetraGraph in Spain and Portugal.

Resolutions at Senzime AB’s (publ) extraordinary general meeting

Press release: Senzime AB (publ) held an extraordinary general meeting on March 5, 2018 in the premises of Advokatfirman Lindahl on Vaksalagatan 10 in Uppsala.